Products - Head and neck cancers | Topic | NICE

Showing 5 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
13 March 2026
Pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck cancer [ID6477]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 August 2026
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC